SR

🧩 Welcome to PatternNotes Tracking liquidity & technical behavior across sessions. Patterns repeat. Notes remember. Liquidity forgets. For study, not signals. Educational & informational study only · NFA

1. THE REACTOR How a barbell reaches the nucleus. By “reactor,” I mean the chain that converts a mechanical workout into a cellular adaptation: force → energy stress → signaling → gene expression → mitochondrial remodeling → myokine output. Every measured node in my genome between the bar and the DNA is favorable or shows no obvious common bottleneck. The only missing input is the bar. 2. THE FORCE BARBELL ↓ ACTN3 C;C — functional α-actinin-3 fast-twitch mechanical capacity ↓ MECHANICAL TENSION ↓ ATP DEMAND ↑ · Ca²⁺ FLUX · ROS ↓ AMPD1 C;C — no deficiency signal ↓ AMPK · CaMK · p38 MAPK 3. THE TRAP p38 is driven partly by contraction-generated H₂O₂. The ROS is part of the signal. ✗ NAC ✗ High-dose Vitamin C ✗ High-dose Vitamin E ✗ Catalase induction from sulforaphane ✗ CoQ10 · ALA · MitoQ High-dose antioxidants can blunt parts of the PGC-1α response to training. My multivitamin contains Vitamin C, Vitamin E, and NAC — the same antioxidant categories implicated in studies showing blunted exercise signaling. Train first. Supplement at night. 4. THE BUILD AMPK · CaMK · p38 · mechanotransduction ↓ EXERCISE-ADAPTATION NETWORK ↓ PGC-1α-associated remodeling (PPARGC1A G;G) ↓ NRF-1 / TFAM → mitochondrial biogenesis AND IN PARALLEL: Exercise-responsive myokine regulation ↓ IL-15 / IL-15Rα ↓ ⚠️ Trans-presentation — cell-to-cell, not free circulation. The weakest link. ↓ NK cells · CD8⁺ cells ↓ ❓ Immune surveillance — unproven. Everything above it is biologically supported, but not equally proven at every arrow. 5. THE DEFENSE FOXO3 — I carry 4 longevity-associated variants. Insulin → PI3K → AKT AKT phosphorylates FOXO3 → exports it from the nucleus → degraded → silent My fasting insulin is 3.2. Chronic insulin-AKT pressure is low. The environment favors FOXO3 activity. The door is open. AMPK is the key. The barbell turns it. My personal notes. Not medical advice

Genome-to-protocol alignment? ACTN3 C;C ↓ fast-twitch recruitment / mechanical output PPARGC1A G;G ↓ favorable PGC-1α-associated remodeling background Combined with resistance training ↓ stronger theoretical environment for mitochondrial adaptation and exercise-responsive myokine signaling My personal notes. Not medical advice

Random thoughts: Humans evolved a selective system to acquire and retain a fungal metabolite that directly activates a mitochondrial sulfur enzyme. That metabolite may help preserve mitochondrial function and exercise capacity. When paired with progressive resistance training, the resulting increase in sustainable muscular work could amplify AMPK-linked mitochondrial and myokine signaling. IL-15, as a muscle-associated cytokine that supports NK and CD8 T-cell biology, may provide one bridge between skeletal-muscle fitness and cancer surveillance. fungal metabolite → human transporter → mitochondrial sulfur enzyme → muscle performance → exercise signaling → myokine biology → immune competence. Speculating 🤔 (unproven thesis) 1. Chronic foundation: Ergothioneine exposure ↓ SLC22A4/OCTN1 uptake and tissue retention ↓ MPST-associated mitochondrial sulfur/redox biology ↓ proposed support of mitochondrial function and exercise capacity 2. Weekly chemical impulses HTB + crucifers + sulforaphane ↓ Polyphenol metabolism + NRF2 + endothelial/gut effects ↓ Lower chronic noise and improved recovery environment 3. Mechanical pulse Progressive resistance training ↓ mechanical tension + energetic stress + Ca²⁺ + redox signaling ↓ AMPK / CaMK / p38 / mechanotransduction ↓ mitochondrial remodeling + hypertrophy signaling + myokine regulation ↓ possible IL-15 / IL-15Rα response 4. Immune relay IL-15 / IL-15Rα biology ↓ NK-cell and memory-CD8 support ↓ possible improvement in immune competence/cancer surveillance A selectively retained dietary compound directly activates a mitochondrial sulfur enzyme; that may improve the operating environment in which skeletal muscle trains. Progressive loading may then strengthen mitochondrial and myokine biology, with IL-15 providing one possible connection to NK and CD8 immune competence. But: IL-15 supports NK cells does not prove lifting produces enough bioavailable IL-15 to strengthen cancer surveillance. And The major theoretical downside is the same MPST/H₂S cytoprotection that might help healthy muscle could also help certain tumors or modify antitumor immunity in an unfavorable direction. Trying to build an excellent muscle-performance environment—but there is no assurance that its immune signal reaches cancer, and no assurance that cancer cannot use the same environment better than muscle does. My personal notes. Not medical advice.

Lots of misinformation regarding aortic dissections that I am seeing, from both non-physicians and unfortunately, physicians. An aortic dissection is not the same thing as an aortic aneurysm. There is no routine screening test for aortic dissection in the general population, unless you either have a first degree relative who had a dissection or aneurysm or have one of the rare heritable thoracic aortic disease syndromes such as Marfans or Ehlers-Danlos. This is per ACC/AHA guidelines. Aortic dissection often occurs without a large preceding aneurysm or in sporadic cases driven by acute hypertension. It is a true emergency medical condition with a high mortality rate, even if the patient makes it to the operating room. The strongest controllable risk factors are keeping blood pressure under control and avoiding hypertension, avoiding smoking cigarettes, keeping cholesterol levels healthy, and avoiding obesity and insulin resistance.

$CRBU 🧬📈

#ICYMI Dr. Binod Dhakal spoke with @MyelomaEurope about the CB-011 data presented at #EHA2026 and what it means for patients. Check out the full interview below. #CellTherapy #CRISPR $CRBU

@ahenryokc $crbu only one on this list i am invested in. My personal notes. Not financial advice

I think we need to establish weekly, possibly daily, mental health checks for those of us who invested in smallcap bio’s. $crbu $fate $prme $allo $beam $sana

Random thoughts: Obesity may be a systemic version of the tumor microenvironment. Could restoring NK metabolic fitness let a lower, tolerable systemic dose of IL-15 agonist actually work? Obesity paradox” in immunotherapy. Obese patients often respond better to checkpoint inhibitors, not worse. If obesity purely broke anti-tumor immunity, that shouldn’t happen. Glp1: What we do know: after stopping semaglutide, roughly two-thirds of lost weight comes back within a year. And the regain is disproportionately fat. So the plausible model is: •On drug: low insulin, low lipid overflow → myosteatosis doesn’t re-accumulate. Transmitter stays clean. •Off drug: fat returns first, muscle doesn’t. You can end up with a worse body composition than you started with. Which means the “cleaning” is rented, not owned — unless you built something while you had the window. That’s an argument for load, not for the drug.

$CRBU a few Sunday thoughts Caribou’s chRDNA (CRISPR hybrid RNA-DNA) technology is a platform, not a single-product tool, because it provides a universal, highly programmable "chassis" for complex genetic engineering. Unlike traditional CRISPR-Cas9, which relies solely on RNA guides, chRDNA uses hybrid guides that significantly increase specificity, minimizing off-target effects while enabling sophisticated, simultaneous edits (multiplexing) that are difficult for other technologies. It differs from and solves problems better than its counterparts: vs. Base Editing: Base editing is often limited to specific, single-nucleotide "point" changes and can struggle with larger, complex genomic reconfigurations. chRDNA excels at precise, large-scale insertions, deletions, and structural changes, allowing for the "armoring" of cells (e.g., immune cloaking or checkpoint disruption) that requires multiple coordinated genomic adjustments. vs. Standard In Vivo Editing: While many in vivo approaches are "one-shot" applications limited by delivery efficiency and the risks of lingering double-strand breaks, chRDNA’s superior precision makes it an ideal engine for ex vivo cell therapies. It produces cleaner, more reliable "off-the-shelf" (allogeneic) cell products by ensuring every cell in a manufactured batch is correctly and safely edited. Essentially, chRDNA turns genome editing into a repeatable industrial process rather than an artisanal, single-target experiment.

@dadbodfamilyguy Great job

The Four-Body Hypothesis Take four people, all 47. One thin. One normal weight. One mildly overweight. One obese. They look nothing alike. But suppose several of them share a hidden condition: skeletal muscle that is fat-infiltrated, insulin-resistant, mitochondrially weak, and metabolically noisy — muscle that has stopped signaling properly. A real metabolic phenotype sits underneath this thought experiment. It has a name. Metabolically obese, normal weight. MONW. Thin outside, fat inside. Normal BMI, visceral fat, intramuscular lipid, insulin resistance. These people can be invisible to BMI, because the scale says they are fine. Body composition, waist measures, insulin markers, and imaging can find them. We just rarely look. So the thin man may not be the control. He may be the same patient in a smaller package. Now put all four on a GLP-1. They will not lose the same weight. They will not lose the same ratio of fat to lean mass. The obese man may shed enormous fat. The thin man may barely move on the scale. The overweight man may lose a disproportionate share of lean tissue. But what if the weight loss is not the output that matters? What if lower insulin, lower energy intake, reduced lipid overflow, and altered nutrient signaling force each body to remodel whatever tissue is most metabolically inefficient — not because the drug recognizes bad muscle, but because bad muscle is what stops being affordable? Different bodies. Different curves. Possibly the same endpoint: less metabolic static, better muscle signaling, restored NK-cell function. The scale would say these are four different experiments. The immune system might say they are one. That is the speculation. And there may already be a hint sitting on a hard drive in Ireland. In the 2023 Dublin study, six months of semaglutide improved NK-cell cytotoxicity, IFN-γ and granzyme B. Only 9 of 20 participants lost more than 5% of body weight — and the authors reported that the immune improvements appeared largely independent of weight loss. So the first question is already answerable, with data that exists: Within that cohort, does NK improvement correlate with baseline BMI, with baseline metabolic dysfunction, or with weight lost? If it tracks weight loss, the convergence hypothesis weakens and this looks more like a fat-loss story. If it doesn't, convergence stays alive — though with n=20, a null correlation could just be low power. And every one of those twenty had obesity, so that cohort can never test four body types. It can only tell us whether the question is worth asking properly. The real test needs a new cohort: thin, normal weight, mildly overweight, obese — matched by age, and stratified by actual muscle quality rather than BMI. One afternoon with the existing spreadsheet can tell us whether the next study is worth running. It cannot replace the next study. And to be clear: none of this says a thin person should take these drugs. It says their muscle may be broken in a way the scale cannot see. The four-body hypothesis was never an argument for the drug. It is an argument against using BMI as a proxy for metabolic or muscle health.

Three years into 15 mg Zepbound. My true pre-drug baseline is gone. That data does not exist and never will. But the group that could answer this question has already done half the experiment. De Barra, Hogan, O’Shea and colleagues in Ireland published the key study in 2023. After six months of semaglutide, people with obesity showed improved NK-cell cytotoxicity, IFN-γ production, and granzyme B responses. Fewer than half lost more than 5% of body weight, so the immune improvement was not easily explained by the scale alone. They measured the lymphocyte. Nobody measured the source. And one detail in their methods keeps bothering me. In the in-vitro arm, isolated NK cells were pretreated with a GLP-1 analogue and then stimulated with exogenous IL-12 and IL-15. They handed the cells IL-15 from a bottle. That experiment showed GLP-1 can alter NK-cell responsiveness. It did not answer where the relevant IL-15 signal comes from in a living person. Skeletal muscle expresses abundant IL-15 mRNA and is a plausible source — or presenter — of IL-15 signaling. Obesity is also associated with altered fiber composition, intramuscular fat, inflammation, and degraded muscle quality. So the question is sitting inside their own study: Is muscle supplying part of the signal, or is it only a bystander? Here is how to test it. Unilateral resistance training. Randomize which leg trains, balanced for limb dominance. Biopsy both legs before training, and again 72–96 hours after the final session — late enough to avoid measuring only an acute exercise spike. The untrained leg is not a perfect control. Cross-education is real, and systemic exercise signals reach both limbs. It controls local mechanical loading, not the entire exercise response. So the design needs three comparisons: • Trained leg vs untrained leg → local loading effect • Both legs vs dose-stable non-trainers → systemic exercise effect • On-drug trainers vs off-drug trainers → whether GLP-1 therapy changes the muscle response to load That last comparison is the one millions of GLP-1 users actually care about. And if load produces a smaller IL-15 response on-drug than off-drug, that is bad news for my thesis and important news for millions of people. I would rather know. Then control the confounder that could ruin the entire experiment: protein intake. GLP-1 users often eat less. If the trained leg fails to respond, that could mean the drug blunted adaptation — or simply that the subject did not consume enough protein or energy to support it. Standardize intake, measure it, or the null result is uninterpretable. Then pair the muscle work with the assays the Irish group already runs — NK cytotoxicity, IFN-γ, granzyme B — plus direct-contact versus transwell co-culture with IL-15Rα blockade. Trained limb increases IL-15/IL-15Rα signaling while the untrained limb does not → a local loading response on top of stable drug exposure. Muscle signaling stays flat while NK function improves anyway → the muscle-source hypothesis weakens. Direct-contact co-culture activates NK cells and the effect disappears under IL-15Rα blockade → the trans-presentation model gains support. Every arm can falsify part of the hypothesis. That is why it is worth running. The Irish group already has the NK-cell expertise and the clinical network. What is missing is the muscle arm: paired biopsies, unilateral loading, contact-versus-transwell co-culture, and IL-15Rα blockade. They are not one biopsy needle away from knowing. They are one protocol away from the first direct test.

Turns out a biopsy alone wouldn't settle it. One sample gives you a number with nothing to compare it to. You need paired biopsies, a loaded limb and an unloaded one, standardized protein, and an IL-15Rα blockade arm — otherwise you can't tell muscle-as-source from muscle-as-bystander. The lab that could do it already exists. Hogan and O'Shea in Dublin have the NK assays, the cohort, and the clinic. In their 2023 study the IL-15 came from the experimenter, not the patient — so the source question is sitting inside their own methods. They are not one biopsy needle away from knowing. They are potentially one protocol away from the first direct test.

@PatternNotes go take the biopsy

PART 7: THE FALSIFIER I would rather state the falsifier than defend the thesis. Nobody has demonstrated that the improved NK-cell function observed after GLP-1 therapy comes from skeletal muscle. De Barra measured the lymphocytes, not the source. I could not find a human study measuring skeletal-muscle IL-15 production, circulating IL-15 signaling, muscle quality, and NK-cell restoration in the same participants. The rival explanation is credible. GLP-1 may act directly on NK cells or through adipose tissue, liver, myeloid cells, the nervous system, or another metabolic intermediary. Reducing lipid toxicity, insulin resistance, leptin signaling, or chronic inflammation may be sufficient. In that world, muscle is a bystander and I am pattern-matching on a coincidence. The trans-presentation problem deepens the challenge. If much of IL-15 biology depends on cell-associated IL-15Rα, serum IL-15 may be the wrong readout. A simple model of freely secreted IL-15 traveling from thigh muscle to distant lymphoid tissue becomes less plausible, though mobile immune cells, soluble receptor complexes, or indirect intermediaries remain possible. The experiment: 1. Measure circulating IL-15, soluble IL-15Rα, and IL-15/IL-15Rα complexes. 2. Biopsy the vastus lateralis for IL-15 and IL-15Rα expression, fiber type, intramuscular fat, mitochondrial function, and inflammatory signaling. 3. Measure NK-cell cytotoxicity, IFN-γ, granzyme B, metabolism, and activating-receptor expression. 4. Compare a fixed low-dose arm with standard titration. 5. Co-culture autologous NK cells with pre- and post-treatment muscle explants using direct-contact and transwell conditions, with and without IL-15 or IL-15Rα blockade. 6. Repeat GLP-1 treatment in an obesity model with inducible skeletal-muscle-specific deletion of Il15 or Il15ra. If post-treatment muscle activates NK cells only during direct contact — and that effect disappears under IL-15Rα blockade — the trans-presentation model gains support. If GLP-1 still restores NK function after muscle-specific Il15 or Il15ra deletion, the muscle-derived pathway is not required. Steps 5 and 6 matter most. Everything before them is correlation. A biopsy. Contact-dependent co-culture. Animal genetics. That this complete chain has not been tested is the most interesting gap in the argument. The impossible idea is not that skeletal muscle influences immune signaling. That part is established. The unresolved idea is that GLP-1 therapy repairs the transmitter, restores muscle-derived IL-15 signaling, and reactivates NK-cell cancer surveillance. That is not a conclusion. It is a clean, tractable, testable hypothesis. Somebody go take the biopsy.